Int J Angiol
DOI: 10.1055/s-0040-1720969
Original Article

Curcumin's Effect on Inflammatory Response following Percutaneous Coronary Intervention in Adult Patients with Stable Coronary Heart Disease

Todung Silalahi
1  Division of Cardiovascular, Department of Internal Medicine, Faculty of Medicine Krida Wacana Christian University, Cipto Mangunkusumo National General Hospital, Jakarta, Indonesia
,
Idrus Alwi
2  Division Cardiovascular, Department of Internal Medicine, Faculty of Medicine Universitas Indonesia, Cipto Mangunkusumo National General Hospital, Jakarta, Indonesia
,
Frans Suyatna
3  Department of Clinical Pharmacology, Faculty of Medicine Universitas Indonesia, Cipto Mangunkusumo National General Hospital, Jakarta, Indonesia
,
Katarina D. Sartika
1  Division of Cardiovascular, Department of Internal Medicine, Faculty of Medicine Krida Wacana Christian University, Cipto Mangunkusumo National General Hospital, Jakarta, Indonesia
› Author Affiliations

Abstract

Cardiovascular diseases play major roles in the health problems worldwide especially in Indonesia. Percutaneous coronary intervention (PCI) is a minimally invasive procedure with relatively low complications. However, high inflammatory response post-PCI has showed adverse events even after administration of standard medication. Previous studies showed that curcumin was able to reduce inflammatory response in adult patients with stable coronary heart disease (CHD). This article determines the efficacy of oral administration of curcumin in reducing inflammatory response post-PCI with stable CHD. A double-blind randomized controlled trial on 50 adult patients comparing curcumin and placebo was performed in Cipto Mangunkusumo General Hospital and Jakarta Heart Center within April and June 2015. Either curcumin (45 mg/day) or placebo was given 7 days prior to PCI until 2 days after PCI. Inflammatory markers (high-sensitivity C-reactive protein [hsCRP] and soluble CD40 ligand [sCD40L]) were measured in three phases (7 days prior PCI, 24 hours post-PCI, and 48 hours post-PCI). There were no significant differences in the reduction of hsCRP and sCD40L between curcumin and placebo groups in three phases of measurement. Curcumin significantly reduce the serum hsCRP (p = 0.006) and sCD40L (p = 0.002) 7 days before PCI to 48 hours post-PCI. The decrement of hsCRP (–14.2% vs. –7.4%) and sCD40L (–24.3% vs. –13.2%) from 24 to 48 hours post-PCI was higher in the curcumin group than placebo group. The administration of curcumin 45 mg dose daily for 7 days prior PCI until 48 hours post-PCI is useful in reducing inflammatory response post-PCI with stable CHD.



Publication History

Publication Date:
29 January 2021 (online)

© 2021. International College of Angiology. This article is published by Thieme.

Thieme Medical Publishers, Inc.
333 Seventh Avenue, 18th Floor, New York, NY 10001, USA